Member Info for EmeraldCarrots

Up 10.68%.

Up 9.28%.

In auction.

Up 8.58%

System that can find twice as many biomarkers than from CtDna analysis alone. Angle's Parsortix device is the only one that can catch live intact circulating tumour cells that are not contaminated or swamped by white blood cells. This makes the Parsortix machine a "must have" to obtain viable CTC's to analyse. Therefore a "must have" for the dual analysis (DNA testing both circulating tumour cells (CTC's) and CtDna) from the same tube of blood).

All IMHO.

Back to £1.40 plus in short order I think.

The least if you ask me. £1.60 to £1.05p on the back of Roches (sequencing by expansion (SBX) technology) not to be launched until next year (if they can sort it out) system which will only compete with a small part of what ONT do anyway! On the face of it a quite ridiculous sp drop. Sp over the next few weeks should be interesting.

All IMHO.

Market cap only £11.5 million with this sp. CRAZY. About time a big player bought in here. What more do they need?? Scottish Government on board. English and Welsh ones will follow IMHO. All this will help boost international sales. "The scottish government have adopted it etc................".

Excellent news.

GOVERNMENT commitment to Genedrive's TWO machines............................................

Is VERY significant. Roll on England and Wales..............

Scottish roll out.

https://www.lse.co.uk/rns/GDR/scottish-government-testing-programme-investment-6nmmchpwz1jnr8h.html

You can read here from the Hornby RNS:-

https://www.lse.co.uk/rns/HRN/proposed-cancellation-of-aim-listing-eiejfwminyw2jda.html

No chance whatsoever with Genedrive as there are no major share holders ---------- at all. It's ludicrous to post GDR might de-list. There is no way the small share holders would vote for it.

All IMHO.

Thousands of small share holders to vote to go private and torpedo the sp? Good luck with that one. LOL!

Plc's can only de-list if the majority of the share holders vote for it. That seems a tad unlikely ! Luckily GDR do not have one or two major share holders that control more than 50% of the shares between them. In fact there are no major holders!!

The players who bought in over the last week or so for the very short term sold out. May have done us all a favour if another RNS turns up next week. I don't see why not as there has been so little news this year!

Https://www.lse.co.uk/rns/GDR/cyp2c19-id-kit-adopted-for-routine-clinical-use-1kyz71paejh9k1b.html

BeardedDragon.

"What happened?"

==================

Apparently it all started with the big bang.

Then we went on from there.

About to be put forward for FDA clearance in the USA. The FDA has already confirmed the machine is unique to the USA market (the CYP2C19-ID). So a machine that will be in great demand in the USA with NO competition at all. What a joke of an sp.

Is never going to work unless the lab is in the hospital. Only the very largest hospitals have their own labs. It's ridiculous. Lab test: You must take a blood sample (rather than a cheek swab for the genedrive machine), so that makes it more dangerous for starters. Then it goes on a courier vehicle to the lab which might be 60 miles away or more. The whole concept is nothing short of totally ridiculous and only someone with no common sense whatsoever (and extremely stupid too) could possibly think a lab test is better.

All IMHO.

Is will be two to four months until the Genedrive MT-RNR1 is cleared for sale in the USA. We will get bought out for 10p a share plus shortly after IMHO. The FDA have already confirmed the MT-RNR1 is unique to the USA market. No other machine available..................................................

All IMHO.

So only a week or so back praising Parsortix and indeed saying why it is better than the other CTC (circulating tumour cell) enrichment systems that are available. It's about using A.I (Resnet50) and bright-field imaging to analyse CTC's.

https://arxiv.org/abs/2503.03410

https://en.wikipedia.org/wiki/Residual_neural_network

So, Angle Plc are now working with Illumina (market cap $17 billion) developing more Illumina assay panels to work with Parsortix (to add to the lung cancer one already available). Plus, Angle work with Astrazeneca (market cap $200 BILLION) and Eisai Inc. (market cap $17 billion). Steady progress and of these 3 multi-billion $ Plc's could easily place one order or do a deal that would make the current sp look completely ridiculous. Any one of them could buy Angle Plc for 50p a share any time they want IMHO, at least for now. One probably will.

All IMHO

Paper about A.I being trained/used to process circulating tumour cells caught from a standard blood sample with Angle Plc' s Parsortix machine. Explains why Parsortix is better than Cellsearch etc....!!!!!!!!!

https://arxiv.org/html/2503.03410